Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2005-12-21
2011-12-27
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S358000, C536S023100
Reexamination Certificate
active
08084576
ABSTRACT:
The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.
REFERENCES:
patent: 6051229 (2000-04-01), Handley et al.
patent: 2002/0038464 (2002-03-01), Charron et al.
patent: 2003/0228592 (2003-12-01), Rogers et al.
patent: 2005/0202559 (2005-09-01), Pownall et al.
patent: 06-141884 (1994-05-01), None
patent: WO 94/16726 (1994-08-01), None
patent: 199855623 (1998-12-01), None
patent: 200104145 (2001-01-01), None
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin binding and mitogenic activities of heparin binding (acidic fibroblast) growth factor-1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Aotsuka, Y. et al.: “Identification of a malignant cell associated antigen recognized by a human monoclonal antibody” European Journal of Cancer & Clinical Oncology. May 1988. vol. 24, No. 5, pp. 829-838. See whole document.
Hagiwara, H. et al.: “Determination of the antigen/epitope that is recognized by Human Monoclonal Antibody CLN-IgG” Human Antibodies. 2001. vol. 10, No. 2, pp. 77-82. See whole document.
Osumi, K. et al.: “Antibody dependent cell mediated cytotoxicity on human cervical carcinoma cell line, ME-180, with human monoclonal antibody” Cancer Letters. 1992. vol. 62, No. 2, pp. 179-183. See whole document.
Fenstermaker, R. et al.: “Immunotherapeutic strategies for malignant glioma” Cancer Control. May/Jun. 2004. vol. 11, No. 3, pp. 181-191. See p. 187, left column, 3rd paragraph.
Shikhman, A. R., et al.: “Distinct pathways regulate faciliated glucose transport in human articular chondrocytes during anabolic and catabolic responses” American Journal of Physiology-Enocrinology and Metabolism. Jan. 28, 2004. vol. 286, pp. E980-E985. See whole document.
Kreitman, R.J.: “Immunotoxins in cancer therapy” Current Opinion in Immunology. 1999. vol. 11, No. 5, pp. 570-578. See whole document.
Moadel R.M., et al.: “Positherapy: targeted nuclear therapy for breast cancer with 18F-2-deoxy-2-fluoro-D-glucose” Cancer Research. Feb. 1, 2005. vol. 65, No. 3, pp. 698-702. See whole document.
Joost, H.G. et al.: “The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review)” Molecular Membrane Biology 2001 vol. 18, No. 4, pp. 247-256.
Rogers, S. et al.: “Differential expression of GLUT12 in breast cancer and normal breast tissue” Cancer Letters (2003) vol. 193, No. 2, pp. 225-233.
Shin B.C., et al.: “Glucose transporter GLUT8 translocation in neurons is not insulin responsive” J. Neurosci. Res. (2004) vol. 75, No. 6, pp. 835-844.
Chen Y. et al.: “Expression and regulation of glucose transporter 8 in rat Leydig cells” J. Endocrinol. (2003) vol. 179, No. 1, pp. 63-72.
Doege, H. et al.: “GLUT8, a novel member of the sugar transport facilitator family with glucose transport activity” J. Biol. Chem. (2000) vol. 275, No. 21, pp. 16275-16280.
Ibberson, M. et al.: “GLUTX1, a novel mammalian glucose transporter expressed in the central nervous system and insulin-sensitive tissues” J Biol. Chem. (2000) vol. 275, No. 7, pp. 4607-4612.
Macheda, M.L. et al.: “Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer” Journal of Cellular Physio. (2005) vol. 202, pp. 654-662.
Goldman Na et al. GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod.Pathol. 2006.
Schmidt U. et al. Endocytosis of the glucose transporter GLUT8 is mediated by interaction of a dileucine motif with the beta2-adaptin subunit of the AP-2 adaptor complex. J Cell Sci. 2006;119:2321-2331.
Lisinski, I., et al., “Targeting of GLUT6 (formerly GLUT9) and GLUT8 in rat adipose cells”, Biochem. J., 2001, vol. 358, pp. 517-522.
Chahal Francina C.
Cizeau Jeannick
Entwistle Joycelyn
Glover Nicholas Ronald
MacDonald Glen Christopher
Bereskin & Parr LLP / S.E.N.C.R.L., s.r.l.
Gravelle Micheline
Gussow Anne M.
Viventia Biotechnologies Inc.
LandOfFree
Cancer associated glucose transporter 8 variant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer associated glucose transporter 8 variant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer associated glucose transporter 8 variant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4315508